文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血患者接受双联抗血小板治疗期间脑室腹腔分流术相关出血的回顾性分析

Hemorrhage associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on a regimen of dual antiplatelet therapy: a retrospective analysis.
PubMed 文献 · J Neurosurg · 2017-11-10

该回顾性分析纳入2009年7月至2016年11月期间在本机构就诊的443例动脉瘤性蛛网膜下腔出血患者,其中80例需行脑室腹腔分流术。32例(40%)因支架辅助弹簧圈或血流导向装置而接受双联抗血小板治疗(DAPT,阿司匹林+氯吡格雷),48例(60%)未接受DAPT。多因素分析显示仅DAPT与分流术相关出血显著相关(OR 31.23,95%CI 2.98-327.32;P=0.0001)。作者结论认为,在接受DAPT的破裂动脉瘤患者中,有临床意义的脑室腹腔分流相关出血风险较低。

要点

  • 80例动脉瘤性蛛网膜下腔出血患者行脑室腹腔分流术,其中32例(40%)接受DAPT。
  • 新发出血8例(10%),7例在DAPT组,1例未在DAPT组。
  • 多因素分析显示仅DAPT与出血显著相关(OR 31.23,95%CI 2.98-327.32;P=0.0001)。

核心结论

  • 在破裂动脉瘤患者中,接受支架辅助弹簧圈或血流导向装置并需DAPT者,脑室腹腔分流术相关有临床意义出血的风险较低。
  • 在血管内治疗不断发展的时代,对于部分动脉瘤性蛛网膜下腔出血患者,支架或血流导向装置是可行选择。

研究设计与样本

  • 回顾性分析,纳入2009年7月至2016年11月在本机构就诊的动脉瘤性蛛网膜下腔出血患者。
  • 共443例患者入院,其中80例因持续性脑积水需行脑室腹腔分流术。
  • 32例(40%)接受支架辅助弹簧圈或血流导向装置并需DAPT(阿司匹林+氯吡格雷),48例(60%)仅接受弹簧圈栓塞(无支架)或显微外科夹闭且未接受DAPT。
  • 采用后退逐步多因素分析比较两组分流术相关出血率。

主要发现

  • 共观察到8例(10%)新发出血,位于脑室腹腔分流管颅内近端导管旁。
  • 7例出血发生在DAPT组,1例发生在非DAPT组。
  • 多因素分析显示仅DAPT与出血显著相关(OR 31.23,95%CI 2.98-327.32;P=0.0001)。
  • DAPT组中1例(3%)因出血相关近端导管堵塞需行分流管翻修。
  • 其余7例出血无临床意义。

临床怎么用

  • 作者结论认为,在接受DAPT的破裂动脉瘤患者中,有临床意义的脑室腹腔分流相关出血风险较低。
  • 作者认为在血管内治疗不断发展的时代,支架或血流导向装置对于部分动脉瘤性蛛网膜下腔出血患者是可行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intracranial stenting and flow diversion require the use of dual antiplatelet therapy (DAPT) to prevent in-stent thrombosis. DAPT may significantly increase the risk of hemorrhagic complications in patients who require subsequent surgical interventions. In this study, the authors sought to investigate whether DAPT is a risk factor for hemorrhagic complications associated with ventriculoperitoneal (VP) shunt placement in patients with aneurysmal subarachnoid hemorrhage (aSAH). Moreover, the authors sought to compare VP shunt complication rates with respect to the shunt's location from the initial external ventricular drain (EVD) site. METHODS: Patients with aSAH who presented to the authors' institution from July 2009 through November 2016 and required VP shunt placement for persistent hydrocephalus were included. The rates of hemorrhagic complications associated with VP shunt placement were compared between patients who were on a regimen of DAPT (aspirin and clopidogrel) for use of a stent or flow diverter, and patients who underwent microsurgical clipping or coiling only and were not on DAPT using a backward stepwise multivariate analysis. Rates of radiographic hemorrhage and infection-related VP shunt revision were compared between patients who underwent VP shunt placement along the same track and those who underwent VP shunt placement at a different site (contralateral or posterior) from the initial EVD. RESULTS: A total of 443 patients were admitted for the management of aSAH. Eighty of these patients eventually required VP shunt placement. Thirty-two patients (40%) had been treated with stent-assisted coiling or flow diverters and required DAPT, whereas 48 patients (60%) had been treated with coiling without stents or surgical clipping and were not on DAPT at the time of VP shunt placement. A total of 8 cases (10%) of new hemorrhage were observed along the intracranial proximal catheter of the VP shunt. Seven of these hemorrhages were observed in patients on DAPT, and 1 occurred in a patient not on DAPT. After multivariate analysis, only DAPT was significantly associated with hemorrhage (OR 31.23, 95% CI 2.98-327.32; p = 0.0001). One patient (3%) on DAPT who experienced hemorrhage required shunt revision for hemorrhage-associated proximal catheter blockage. The remaining 7 hemorrhages were clinically insignificant. The difference in rates of hemorrhage between shunt placement along the same track and placement at a different site of 0.07 was not significant (6/47 vs 2/32, p = 0.46). The difference in infection-related VP shunt revision rate was not significantly different (1/47 vs 3/32, p = 0.2978). CONCLUSIONS: This clinical series confirms that, in patients with ruptured aneurysms who are candidates for stent-assisted coiling or flow diversion, the risk of clinically significant VP shunt-associated hemorrhage with DAPT is low. In an era of evolving endovascular therapeutics, stenting or flow diversion is a viable option in select aSAH patients.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hudson JS, Nagahama Y, Nakagawa D, et al. Hemorrhage associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on a regimen of dual antiplatelet therapy: a retrospective analysis. J Neurosurg. 2017. PMID: 29125410. doi:10.3171/2017.5.JNS17642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。